Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trial

• Nicolas Penel,
• Ulrich Keilholz,
• Ani Balmanoukian,
• Manish R Patel,
• Sanjay Goel,
• Keun-Wook Lee,
• Alain Mita,
• Christophe Le Tourneau,
• Deborah J Wong,
• Patrick Schöffski,
• Marcis Bajars,
• Amaury Daste,
• Hans Juergen Grote,
• Dongli Zhou,
• Michael S Gordon,
• Martin Gutierrez,
• Damien Vansteene,
• Joël Guigay

Affiliations

Nicolas Penel

Department of Medical Oncology, Lille University & Oscar Lambret Cancer Center, Lille, France

Ulrich Keilholz

Charité Comprehensive Cancer Center, Berlin, Germany

Ani Balmanoukian

The Angeles Clinic and Research Institute, Los Angeles, California, USA

Manish R Patel

Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, Florida, USA

Sanjay Goel

Montefiore Medical Center, Albert Einstein College of Medicine, New York, New York, USA

Keun-Wook Lee

Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seoul, South Korea

Alain Mita

Cedars-Sinai Medical Center, Los Angeles, California, USA

Christophe Le Tourneau

Department of Drug Development and Innovation, Institut Curie, Paris-Saclay University, Paris, France

Deborah J Wong

Department of Medicine, UCLA, Los Angeles, California, USA

Patrick Schöffski

Department of General Medical Oncology, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium

Marcis Bajars

Merck Healthcare KGaA, Darmstadt, Germany

Amaury Daste

Groupe Hospitalier Saint André - Hôpital Saint André, Bordeaux, France

Hans Juergen Grote

Merck Healthcare KGaA, Darmstadt, Germany

Dongli Zhou

Merck Serono (Beijing) Pharmaceutical R&D Co., Ltd., Beijing, China, an affiliate of Merck KGaA, Beijing, China

Michael S Gordon

HonorHealth Research Institute, Scottsdale, Arizona, USA

Martin Gutierrez

Hackensack University Medical Center, Hackensack, New Jersey, USA

Damien Vansteene

Département d`Oncologie Médicale, Institut de Cancérologie de l`Ouest, site René Gauducheau, Saint Herblain, France

Joël Guigay

Antoine Lacassagne Cancer Center, FHU OncoAge Université Côte d’Azur, Nice, France